{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"MDT","limit":50},"count":50,"signals":[{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ny business so as to require such qualification, except where the failure to be so  7  qualified in any such jurisdiction would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the business, properties, management, financial position or results of operations of Parent and its subsidiaries, taken as a whole (a Material Adverse Effect); and each of Parents subsidiaries tha","filed_date":"2025-09-16","accession":"0001193125-25-205061","full_text":"https://origin.rootz.global/static/filing/0001193125-25-205061.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"risk_factor","strength":100,"match_count":13,"context":"conducted a risk assessment of its compensation policies and practices during fiscal year 2025 and concluded that such policies and practices do not create risks that are reasonably likely to have a material adverse effect on the Company. The framework for the assessment was developed using materials from the Compensation and Talent Committees independent consultant, Semler Brossy Consulting Group LLC (Semler Brossy).","filed_date":"2025-08-25","accession":"0001613103-25-000151","full_text":"https://origin.rootz.global/static/filing/0001613103-25-000151.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"strategic_event","strength":100,"match_count":50,"context":"Committee to Set Auditor Remuneration | | | 76 | | | CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS | 6 | | | | | PROPOSAL 1Election of Directors | 11 | PROPOSAL 3Advisory Resolution to Approve Named Executive Officer Compensation (Say-On-Pay) | 78 | | | Directors and Nominees | 12 | | | | | CORPORATE GOVERNANCE | 18 | PROPOSAL 4Renewal of the Boards Authority to Issue Shares Under Irish Law | 80 | | | Corporate G","filed_date":"2025-08-25","accession":"0001613103-25-000151","full_text":"https://origin.rootz.global/static/filing/0001613103-25-000151.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"restructuring","strength":100,"match_count":16,"context":"sures; our expectations regarding changes to patient standards of care; our ability to identify and maintain successful business partnerships; the elimination of certain positions or costs related to restructuring initiatives; outcomes in our litigation matters and governmental proceedings and investigations; general economic conditions; the adequacy of available working capital and our working capital needs; our payment","filed_date":"2025-06-20","accession":"0001613103-25-000091","full_text":"https://origin.rootz.global/static/filing/0001613103-25-000091.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"risk_factor","strength":100,"match_count":65,"context":"s, inventors, trainers, and public speakers. If we are unable to maintain strong relationships with these professionals, the development and marketing of our products could suffer, which could have a material adverse effect on our business, results of operations, financial condition, and cash flows. We have debt obligations that create risk. We are required to use a portion of our operating cash flow to pay interest or","filed_date":"2025-06-20","accession":"0001613103-25-000091","full_text":"https://origin.rootz.global/static/filing/0001613103-25-000091.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"strategic_event","strength":100,"match_count":45,"context":"73 | | | Directors and Nominees | 12 | | | | | CORPORATE GOVERNANCE | 17 | | | Corporate Governance Principles | 17 | | | Board Performance Evaluations | 17 | PROPOSAL 3Advisory Resolution to Approve Named Executive Officer Compensation (Say-On-Pay) | 75 | | | Lead Independent Director and Chairman; Executive Sessions | 17 | | | Board Role in Risk Oversight | 18 | | | Compensation Risk Assessment | 19 | | | Committees o","filed_date":"2024-08-09","accession":"0001613103-24-000124","full_text":"https://origin.rootz.global/static/filing/0001613103-24-000124.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"restructuring","strength":100,"match_count":24,"context":"sures; our expectations regarding changes to patient standards of care; our ability to identify and maintain successful business partnerships; the elimination of certain positions or costs related to restructuring initiatives; outcomes in our litigation matters and governmental proceedings and investigations; general economic conditions; the adequacy of available working capital and our working capital needs; our payment","filed_date":"2024-06-20","accession":"0001613103-24-000072","full_text":"https://origin.rootz.global/static/filing/0001613103-24-000072.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"platform_shift","strength":100,"match_count":13,"context":"efits of integrating previous acquisitions; anticipated timing for United States (U.S.) Food and Drug Administration (U.S. FDA) and non-U.S. regulatory approval of new products; increased presence in new markets, including markets outside the U.S.; changes in the market and our market share; our ability to meet growing demand for our existing products; acquisitions and investment initiatives, including the","filed_date":"2024-06-20","accession":"0001613103-24-000072","full_text":"https://origin.rootz.global/static/filing/0001613103-24-000072.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"risk_factor","strength":100,"match_count":62,"context":"s, inventors, trainers, and public speakers. If we are unable to maintain strong relationships with these professionals, the development and marketing of our products could suffer, which could have a material adverse effect on our business, results of operations, financial condition, and cash flows. We have debt obligations that create risk. We are required to use a portion of our operating cash flow to pay interest or","filed_date":"2024-06-20","accession":"0001613103-24-000072","full_text":"https://origin.rootz.global/static/filing/0001613103-24-000072.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"restructuring","strength":100,"match_count":15,"context":"opment expense | 695 | 688 | 2,060 | 2,055 | | | Selling, general, and administrative expense | 2,673 | 2,615 | 7,971 | 7,799 | | | Amortization of intangible assets | 419 | 431 | 1,274 | 1,275 | | | Restructuring charges, net | 20 | 38 | 114 | 81 | | | Certain litigation charges | | | 105 | | | | Other operating expense (income), net | 17 | (125) | (13) | (187) | | | Operating profit | 1,483 | 1,392 | 4,091 | 3,920 |","filed_date":"2024-02-27","accession":"0001613103-24-000011","full_text":"https://origin.rootz.global/static/filing/0001613103-24-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"restructuring","strength":100,"match_count":15,"context":",365 | | | 1,368 | | | | Selling, general, and administrative expense | 2,686 | | | 2,617 | | | 5,299 | | | 5,184 | | | | Amortization of intangible assets | 425 | | | 421 | | | 855 | | | 844 | | | | Restructuring charges, net | 40 | | | 30 | | | 94 | | | 44 | | | | Certain litigation charges | 65 | | | | | | 105 | | | | | | | Other operating income, net | (31) | | | (97) | | | (30) | | | (62) | | | | Operating profit","filed_date":"2023-11-30","accession":"0001613103-23-000149","full_text":"https://origin.rootz.global/static/filing/0001613103-23-000149.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"restructuring","strength":100,"match_count":14,"context":"development expense | 668 | | | 692 | | | | | | | | Selling, general, and administrative expense | 2,613 | | | 2,567 | | | | | | | | Amortization of intangible assets | 429 | | | 423 | | | | | | | | Restructuring charges, net | 54 | | | 14 | | | | | | | | Certain litigation charges | 40 | | | | | | | | | | | Other operating expense, net | 1 | | | 35 | | | | | | | | Operating profit | 1,268 | | | 1,125 | | | | | | | |","filed_date":"2023-08-31","accession":"0001613103-23-000128","full_text":"https://origin.rootz.global/static/filing/0001613103-23-000128.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"strategic_event","strength":100,"match_count":41,"context":"and Nominees | 13 | | | | | | | | | CORPORATE GOVERNANCE | 19 | | | | Corporate Governance Principles | 19 | | | | | | Board Performance Evaluations | 19 | | PROPOSAL 3Advisory Resolution to Approve Named Executive Officer Compensation (Say-On-Pay) | 77 | | | Lead Independent Director and Chairman; Executive Sessions | 19 | | | | Board Role in Risk Oversight | 20 | | | | Compensation Risk Assessment | 21 | | | | | | Co","filed_date":"2023-08-11","accession":"0001613103-23-000108","full_text":"https://origin.rootz.global/static/filing/0001613103-23-000108.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"restructuring","strength":100,"match_count":25,"context":"sures; our expectations regarding changes to patient standards of care; our ability to identify and maintain successful business partnerships; the elimination of certain positions or costs related to restructuring initiatives; outcomes in our litigation matters and governmental proceedings and investigations; general economic conditions; the adequacy of available working capital and our working capital needs; our payment","filed_date":"2023-06-22","accession":"0001613103-23-000040","full_text":"https://origin.rootz.global/static/filing/0001613103-23-000040.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"platform_shift","strength":100,"match_count":15,"context":"efits of integrating previous acquisitions; anticipated timing for United States (U.S.) Food and Drug Administration (U.S. FDA) and non-U.S. regulatory approval of new products; increased presence in new markets, including markets outside the U.S.; changes in the market and our market share; acquisitions and investment initiatives, including the timing of regulatory approvals as well as integration of acqui","filed_date":"2023-06-22","accession":"0001613103-23-000040","full_text":"https://origin.rootz.global/static/filing/0001613103-23-000040.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"risk_factor","strength":100,"match_count":34,"context":", market and sell new and improved products. If we are unable to maintain strong relationships with these professionals, the development and marketing of our products could suffer, which could have a material adverse effect on our business, results of operations, financial condition, and cash flows. We have debt obligations that create risk. We are required to use a portion of our operating cash flow to pay interest or","filed_date":"2023-06-22","accession":"0001613103-23-000040","full_text":"https://origin.rootz.global/static/filing/0001613103-23-000040.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ct any business so as to require such qualification, except where the failure to be so qualified in any such jurisdiction would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the business, properties, management, financial position or results of operations of Parent and its subsidiaries, taken as a whole (a Material Adverse Effect); and each of Parents subsidiaries tha","filed_date":"2023-03-30","accession":"0001193125-23-085642","full_text":"https://origin.rootz.global/static/filing/0001193125-23-085642.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"restructuring","strength":100,"match_count":16,"context":"| | | 2,094 | | | | Selling, general, and administrative expense | 2,615 | | | 2,561 | | | 7,799 | | | 7,723 | | | | Amortization of intangible assets | 431 | | | 432 | | | 1,275 | | | 1,298 | | | | Restructuring charges, net | 38 | | | 12 | | | 81 | | | 32 | | | | Certain litigation charges, net | | | | 35 | | | | | | 95 | | | | Other operating (income) expense, net | (125) | | | (63) | | | (187) | | | 719 | | | | O","filed_date":"2023-03-01","accession":"0001613103-23-000008","full_text":"https://origin.rootz.global/static/filing/0001613103-23-000008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"restructuring","strength":100,"match_count":24,"context":",368 | | | 1,426 | | | | Selling, general, and administrative expense | 2,617 | | | 2,615 | | | 5,184 | | | 5,163 | | | | Amortization of intangible assets | 421 | | | 431 | | | 844 | | | 866 | | | | Restructuring charges, net | 30 | | | 10 | | | 44 | | | 21 | | | | Certain litigation charges, net | | | | 34 | | | | | | 60 | | | | Other operating (income) expense, net | (97) | | | 21 | | | (62) | | | 781 | | | | Opera","filed_date":"2022-12-01","accession":"0001613103-22-000063","full_text":"https://origin.rootz.global/static/filing/0001613103-22-000063.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"platform_shift","strength":100,"match_count":13,"context":"t for the three and six months ended October28, 2022 and October29, 2021: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | U.S.(1) | | Non-U.S. Developed Markets(2) | | Emerging Markets(3) | | | | Three months ended | | Three months ended | | Three months ended | | | (in millions) | October 28, 2022 | | October 29, 2021 | | October 28, 2022 | | October 29, 2021 | | October 28, 2022","filed_date":"2022-12-01","accession":"0001613103-22-000063","full_text":"https://origin.rootz.global/static/filing/0001613103-22-000063.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ct any business so as to require such qualification, except where the failure to be so qualified in any such jurisdiction would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the business, properties, management, financial position or results of operations of Parent and its subsidiaries, taken as a whole (a Material Adverse Effect); and each of Parents subsidiaries tha","filed_date":"2022-09-21","accession":"0001193125-22-248112","full_text":"https://origin.rootz.global/static/filing/0001193125-22-248112.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"restructuring","strength":100,"match_count":22,"context":"development expense | 692 | | | 750 | | | | | | | | Selling, general, and administrative expense | 2,567 | | | 2,547 | | | | | | | | Amortization of intangible assets | 423 | | | 436 | | | | | | | | Restructuring charges, net | 14 | | | 11 | | | | | | | | Certain litigation charges, net | | | | 26 | | | | | | | | Other operating expense, net | 35 | | | 760 | | | | | | | | Operating profit | 1,125 | | | 859 | | | | |","filed_date":"2022-09-01","accession":"0001613103-22-000046","full_text":"https://origin.rootz.global/static/filing/0001613103-22-000046.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"strategic_event","strength":100,"match_count":38,"context":"nd Binding Authorization of the Board of Directors, Acting Through the Audit Committee, to Set Auditor Remuneration |  | | |  |  | | |  PROPOSAL 3 |  |  |  79 |  | | |  Advisory Resolution to Approve Named Executive Officer Compensation (Say-On-Pay) |  | | |  |  | | |  PROPOSAL 4 |  |  |  81 |  | | |  Renewal of the Boards Authority to Issue Shares Under Irish Law |  | | |  |  | | |  PROPOSAL 5 |  |  |  82 |  | | |  Ren","filed_date":"2022-08-19","accession":"0001193125-22-225369","full_text":"https://origin.rootz.global/static/filing/0001193125-22-225369.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"restructuring","strength":100,"match_count":22,"context":"sures; our expectations regarding changes to patient standards of care; our ability to identify and maintain successful business partnerships; the elimination of certain positions or costs related to restructuring initiatives; outcomes in our litigation matters and governmental proceedings and investigations; general economic conditions; the adequacy of available working capital and our working capital needs; our payment","filed_date":"2022-06-23","accession":"0001613103-22-000023","full_text":"https://origin.rootz.global/static/filing/0001613103-22-000023.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"platform_shift","strength":100,"match_count":16,"context":"efits of integrating previous acquisitions; anticipated timing for United States (U.S.) Food and Drug Administration (U.S. FDA) and non-U.S. regulatory approval of new products; increased presence in new markets, including markets outside the U.S.; changes in the market and our market share; acquisitions and investment initiatives, including the timing of regulatory approvals as well as integration of acqui","filed_date":"2022-06-23","accession":"0001613103-22-000023","full_text":"https://origin.rootz.global/static/filing/0001613103-22-000023.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"risk_factor","strength":100,"match_count":34,"context":", market and sell new and improved products. If we are unable to maintain strong relationships with these professionals, the development and marketing of our products could suffer, which could have a material adverse effect on our business, results of operations, financial condition, and cash flows. We have debt obligations that create risk. We are required to use a portion of our operating cash flow to pay interest or","filed_date":"2022-06-23","accession":"0001613103-22-000023","full_text":"https://origin.rootz.global/static/filing/0001613103-22-000023.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"risk_factor","strength":100,"match_count":24,"context":"n with true leases or operating leases shall not constitute a Lien for purposes of this Agreement.  Loans means the loans made by the Lenders to the Company pursuant to Article II of this Agreement.  Material Adverse Effect means a material adverse effect on (a) the business, property, operations or financial condition of Parent and its Subsidiaries taken as a whole, (b) the ability of the Credit Parties to perform any","filed_date":"2022-05-02","accession":"0001193125-22-135320","full_text":"https://origin.rootz.global/static/filing/0001193125-22-135320.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"restructuring","strength":100,"match_count":26,"context":"| | | 1,861 | | | | Selling, general, and administrative expense | 2,561 | | | 2,537 | | | 7,723 | | | 7,553 | | | | Amortization of intangible assets | 432 | | | 453 | | | 1,298 | | | 1,337 | | | | Restructuring charges, net | 12 | | | 83 | | | 32 | | | 235 | | | | Certain litigation charges, net | 35 | | | 122 | | | 95 | | | 118 | | | | Other operating (income) expense, net | (63) | | | 82 | | | 719 | | | 116 | | |","filed_date":"2022-03-03","accession":"0001613103-22-000011","full_text":"https://origin.rootz.global/static/filing/0001613103-22-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"platform_shift","strength":100,"match_count":14,"context":"for the three and nine months ended January28, 2022 and January29, 2021: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | U.S.(1) | | Non-U.S. Developed Markets(2) | | Emerging Markets(3) | | | | Three months ended | | Three months ended | | Three months ended | | | (in millions) | January 28, 2022 | | January 29, 2021 | | January 28, 2022 | | January 29, 2021 | | January 28, 2022","filed_date":"2022-03-03","accession":"0001613103-22-000011","full_text":"https://origin.rootz.global/static/filing/0001613103-22-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"restructuring","strength":100,"match_count":24,"context":",426 | | | 1,260 | | | | Selling, general, and administrative expense | 2,615 | | | 2,600 | | | 5,163 | | | 5,017 | | | | Amortization of intangible assets | 431 | | | 443 | | | 866 | | | 884 | | | | Restructuring charges, net | 10 | | | 97 | | | 21 | | | 150 | | | | Certain litigation charges, net | 34 | | | 84 | | | 60 | | | (4) | | | | | | | | | | | | | | Other operating expense, net | 21 | | | 149 | | | 781 | | |","filed_date":"2021-12-02","accession":"0001613103-21-000062","full_text":"https://origin.rootz.global/static/filing/0001613103-21-000062.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"platform_shift","strength":100,"match_count":13,"context":"t for the three and six months ended October29, 2021 and October30, 2020: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | U.S.(1) | | Non-U.S. Developed Markets(2) | | Emerging Markets(3) | | | | Three months ended | | Three months ended | | Three months ended | | | (in millions) | October 29, 2021 | | October 30, 2020 | | October 29, 2021 | | October 30, 2020 | | October 29, 2021","filed_date":"2021-12-02","accession":"0001613103-21-000062","full_text":"https://origin.rootz.global/static/filing/0001613103-21-000062.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"risk_factor","strength":100,"match_count":9,"context":"and $0.4billion, respectively. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Companys consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in other accrued expenses and other liabilities on the consolidated balance sheet","filed_date":"2021-12-02","accession":"0001613103-21-000062","full_text":"https://origin.rootz.global/static/filing/0001613103-21-000062.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"restructuring","strength":100,"match_count":34,"context":"development expense | 750 | | | 621 | | | | | | | | Selling, general, and administrative expense | 2,547 | | | 2,417 | | | | | | | | Amortization of intangible assets | 436 | | | 440 | | | | | | | | Restructuring charges, net | 11 | | | 53 | | | | | | | | Certain litigation charges, net | 26 | | | (88) | | | | | | | | | | | | | | | | | | Other operating expense (income), net | 760 | | | (114) | | | | | | | | Operatin","filed_date":"2021-09-02","accession":"0001613103-21-000042","full_text":"https://origin.rootz.global/static/filing/0001613103-21-000042.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"strategic_event","strength":100,"match_count":47,"context":"AUDITOR AND BINDING AUTHORIZATION OF THE BOARD OF DIRECTORS, ACTING THROUGH THE AUDIT COMMITTEE, TO SET AUDITOR REMUNERATION |  |  |  76 |  | | |  |  | | |  PROPOSAL 3 ADVISORY RESOLUTION TO APPROVE NAMED EXECUTIVE OFFICER COMPENSATION (SAY-ON-PAY) |  |  |  77 |  | | |  |  | | |  PROPOSAL 4 ADVISORY VOTE ON FREQUENCY OF SAY-ON-PAY VOTES |  |  |  78 |  | | |  |  | | |  PROPOSAL 5 TO APPROVE THE 2021 MEDTRONIC PLC LONG T","filed_date":"2021-08-27","accession":"0001193125-21-259369","full_text":"https://origin.rootz.global/static/filing/0001193125-21-259369.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"restructuring","strength":100,"match_count":40,"context":"sures; our expectations regarding changes to patient standards of care; our ability to identify and maintain successful business partnerships; the elimination of certain positions or costs related to restructuring initiatives; outcomes in our litigation matters and governmental proceedings and investigations; general economic conditions; the adequacy of available working capital and our working capital needs; our payment","filed_date":"2021-06-25","accession":"0001613103-21-000027","full_text":"https://origin.rootz.global/static/filing/0001613103-21-000027.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"platform_shift","strength":100,"match_count":17,"context":"efits of integrating previous acquisitions; anticipated timing for United States (U.S.) Food and Drug Administration (U.S. FDA) and non-U.S. regulatory approval of new products; increased presence in new markets, including markets outside the U.S.; changes in the market and our market share; acquisitions and investment initiatives, as well as integration of acquired companies into our operations; the resolu","filed_date":"2021-06-25","accession":"0001613103-21-000027","full_text":"https://origin.rootz.global/static/filing/0001613103-21-000027.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"risk_factor","strength":100,"match_count":37,"context":", market and sell new and improved products. If we are unable to maintain strong relationships with these professionals, the development and marketing of our products could suffer, which could have a material adverse effect on our business, results of operations, financial condition, and cash flows. Our substantial leverage and debt service obligations could adversely affect our business. At April 30, 2021, we had appro","filed_date":"2021-06-25","accession":"0001613103-21-000027","full_text":"https://origin.rootz.global/static/filing/0001613103-21-000027.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"restructuring","strength":100,"match_count":41,"context":"| | | 1,763 | | | | Selling, general, and administrative expense | 2,537 | | | 2,587 | | | 7,553 | | | 7,750 | | | | Amortization of intangible assets | 453 | | | 436 | | | 1,337 | | | 1,317 | | | | Restructuring charges, net | 83 | | | 13 | | | 235 | | | 87 | | | | Certain litigation charges, net | 122 | | | 108 | | | 118 | | | 276 | | | | | | | | | | | | | | Other operating expense (income), net | 82 | | | (39) | |","filed_date":"2021-03-05","accession":"0001613103-21-000009","full_text":"https://origin.rootz.global/static/filing/0001613103-21-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"platform_shift","strength":100,"match_count":16,"context":"for the three and nine months ended January29, 2021 and January24, 2020: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | U.S.(1) | | Non-U.S. Developed Markets(2) | | Emerging Markets(3) | | | | Three months ended | | Three months ended | | Three months ended | | | (in millions) | January 29, 2021 | | January 24, 2020 | | January 29, 2021 | | January 24, 2020 | | January 29, 2021","filed_date":"2021-03-05","accession":"0001613103-21-000009","full_text":"https://origin.rootz.global/static/filing/0001613103-21-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"restructuring","strength":100,"match_count":39,"context":",260 | | | 1,190 | | | | Selling, general, and administrative expense | 2,600 | | | 2,620 | | | 5,017 | | | 5,163 | | | | Amortization of intangible assets | 443 | | | 441 | | | 884 | | | 881 | | | | Restructuring charges, net | 97 | | | 27 | | | 150 | | | 74 | | | | Certain litigation charges, net | 84 | | | 121 | | | (4) | | | 168 | | | | | | | | | | | | | | Other operating expense, net | 149 | | | 149 | | | 35 | |","filed_date":"2020-12-03","accession":"0001613103-20-000051","full_text":"https://origin.rootz.global/static/filing/0001613103-20-000051.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"platform_shift","strength":100,"match_count":16,"context":"the three and six months ended October30, 2020 and October25, 2019: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | U.S.(1)(4) | | Non-U.S. Developed Markets(2)(4) | | Emerging Markets(3)(4) | | | | Three months ended | | Three months ended | | Three months ended | | | (in millions) | October 30, 2020 | | October 25, 2019 | | October 30, 2020 | | October 25, 2019 | | October 30, 2","filed_date":"2020-12-03","accession":"0001613103-20-000051","full_text":"https://origin.rootz.global/static/filing/0001613103-20-000051.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"risk_factor","strength":100,"match_count":13,"context":"ct any business so as to require such qualification, except where the failure to be so qualified in any such jurisdiction would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the business, properties, management, financial position or results of operations of Parent and its subsidiaries, taken as a whole (a Material Adverse Effect); and each of Parents subsidiaries tha","filed_date":"2020-09-29","accession":"0001193125-20-257811","full_text":"https://origin.rootz.global/static/filing/0001193125-20-257811.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"restructuring","strength":100,"match_count":36,"context":"366 | | | | Research and development expense | 621 | | | 587 | | | | Selling, general, and administrative expense | 2,417 | | | 2,543 | | | | Amortization of intangible assets | 440 | | | 440 | | | | Restructuring charges, net | 53 | | | 47 | | | | Certain litigation charges, net | (88) | | | 47 | | | | | | | | | | Other operating income, net | (114) | | | (22) | | | | Operating profit | 673 | | | 1,485 | | | | Other","filed_date":"2020-09-03","accession":"0001613103-20-000033","full_text":"https://origin.rootz.global/static/filing/0001613103-20-000033.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"strategic_event","strength":100,"match_count":38,"context":"AUDITOR AND BINDING AUTHORIZATION OF THE BOARD OF DIRECTORS, ACTING THROUGH THE AUDIT COMMITTEE, TO SET AUDITOR REMUNERATION |  |  |  72 |  | | |  |  | | |  PROPOSAL 3 ADVISORY RESOLUTION TO APPROVE NAMED EXECUTIVE OFFICER COMPENSATION (SAY-ON-PAY) |  |  |  73 |  | | |  |  | | |  PROPOSAL 4 RENEWAL OF THE BOARDS AUTHORITY TO ISSUE SHARES UNDER IRISH LAW |  |  |  74 |  | | |  |  | | |  PROPOSAL 5 RENEWAL OF THE BOARDS A","filed_date":"2020-08-14","accession":"0001193125-20-220558","full_text":"https://origin.rootz.global/static/filing/0001193125-20-220558.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"restructuring","strength":100,"match_count":24,"context":"sures; our expectations regarding changes to patient standards of care; our ability to identify and maintain successful business partnerships; the elimination of certain positions or costs related to restructuring initiatives; outcomes in our litigation matters and governmental proceedings and investigations; general economic conditions; the adequacy of available working capital and our working capital needs; our payment","filed_date":"2020-06-19","accession":"0001613103-20-000021","full_text":"https://origin.rootz.global/static/filing/0001613103-20-000021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"platform_shift","strength":100,"match_count":25,"context":"efits of integrating previous acquisitions; anticipated timing for United States (U.S.) Food and Drug Administration (U.S. FDA) and non-U.S. regulatory approval of new products; increased presence in new markets, including markets outside the U.S.; changes in the market and our market share; acquisitions and investment initiatives, as well as integration of acquired companies into our operations; the resolu","filed_date":"2020-06-19","accession":"0001613103-20-000021","full_text":"https://origin.rootz.global/static/filing/0001613103-20-000021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"risk_factor","strength":100,"match_count":33,"context":"o obtain or maintain marketing clearance for our new products or enhancements or modifications to existing products, and the failure to maintain approvals or obtain approval or clearance could have a material adverse effect on our business, results of operations, financial condition and cash flows. Even if we are able to obtain approval or clearance, it may: take a significant amount of time, require the expenditure of","filed_date":"2020-06-19","accession":"0001613103-20-000021","full_text":"https://origin.rootz.global/static/filing/0001613103-20-000021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"strategic_event","strength":100,"match_count":9,"context":"in these capacities, and their business experiences. There are no family relationships among any of the officers named, nor is there any arrangement or understanding pursuant to which any person was selected as an officer. The following table shows the name, age, and position as of April24, 2020 of each of our executive officers: | | | | | | | | | | | | | | | | | | Name | | Age | | Position with the Company | | | Omar","filed_date":"2020-06-19","accession":"0001613103-20-000021","full_text":"https://origin.rootz.global/static/filing/0001613103-20-000021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"risk_factor","strength":100,"match_count":24,"context":"ion with true leases or operating leases shall not constitute a Lien for purposes of this Agreement. Loans means the loans made by the Lenders to the Company pursuant to Article II of this Agreement. Material Adverse Effect means a material adverse effect on (a) the business, property, operations or financial condition of Parent and its Subsidiaries taken as a whole, (b) the ability of the Credit Parties to perform any","filed_date":"2020-05-13","accession":"0001613103-20-000016","full_text":"https://origin.rootz.global/static/filing/0001613103-20-000016.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MDT","company":"Medtronic plc","exchange":"NYSE","sector":"Electromedical & Electrotherapeutic Apparatus","signal_type":"restructuring","strength":100,"match_count":30,"context":"| | | 1,736 | | | | Selling, general, and administrative expense | 2,587 | | | 2,596 | | | 7,750 | | | 7,798 | | | | Amortization of intangible assets | 436 | | | 436 | | | 1,317 | | | 1,327 | | | | Restructuring charges, net | 13 | | | 26 | | | 87 | | | 112 | | | | Certain litigation charges | 108 | | | 63 | | | 276 | | | 166 | | | | | | | | | | | | | | Other operating (income) expense, net | (39) | | | 57 | | | 88","filed_date":"2020-02-28","accession":"0001613103-20-000007","full_text":"https://origin.rootz.global/static/filing/0001613103-20-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"4b548294fbc3c7865356e30e29af1d5471a9f8145a76493b6092e88d981f43c7","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"8ed6eeff4428835dbccbfdc16632f476fb80cd5dc89ff2743184efdff2fbe932","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":431,"hourly_limit":500,"remaining":69,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}